Stuart Ince
Impact in
-
- Cancer-related Molecular Pathways
-
- Fibroblast Growth Factor Research
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- PI3K/AKT/mTOR signaling in cancer
- Kruppel-like factors research
Papers in
-
- Fibroblast Growth Factor Research 7
- PI3K/AKT/mTOR signaling in cancer 5
- Protein Degradation and Inhibitors 3
- Epigenetics and DNA Methylation 2
- Oncology 9
- Cancer Treatment and Pharmacology 5
- Cancer-related Molecular Pathways 5
- Co-authors
- Dominik Mumberg (10 shared papers)Karl Ziegelbauer (10 shared papers)Franz von Nussbaum (7 shared papers)Arne Scholz (7 shared papers)Peter Ellinghaus (9 shared papers)Oliver Politz (5 shared papers)Mélanie Héroult (5 shared papers)Ulf Bömer (3 shared papers)
- Journals
- Cancer Research (13 papers)Journal of Clinical Oncology (2 papers)International Journal of Cancer (2 papers)Molecular Cancer Therapeutics (1 paper)Journal of Medicinal Chemistry (1 paper)
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
Stuart Ince
21 papers receiving 299 citations
Peers
Comparison fields: 5 of 37
- Oncology 92
- Molecular Biology 210
- Pulmonary and Respiratory Medicine 62
- Cancer Research 26
- Organic Chemistry 54
Countries citing papers authored by Stuart Ince
This map shows the geographic impact of Stuart Ince's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart Ince with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart Ince more than expected).
Fields of papers citing papers by Stuart Ince
This network shows the impact of papers produced by Stuart Ince. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart Ince. The network helps show where Stuart Ince may publish in the future.
Co-authors
The 25 scholars most cited alongside Stuart Ince, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 74 | |
| 2 | 2021 | 58 | |
| 3 | 2016 | 53 | |
| 4 | 2017 | 27 | |
| 5 | 2018 | 17 | |
| 6 | 2016 | 17 | |
| 7 | 2018 | 11 | |
| 8 | 2014 | 10 | |
| 9 | 2015 | 9 | |
| 10 | 2015 | 6 | |
| 11 | 2015 | 6 | |
| 12 | 2017 | 4 | |
| 13 | 2016 | 3 | |
| 14 | 2014 | 3 | |
| 15 | 2016 | 2 | |
| 16 | 2013 | 2 | |
| 17 | ZK 261991. a novel VEGFR inhibitor for tumor therapy | 2007 | 1 |
| 18 | 2014 | 1 | |
| 19 | 2017 | 1 | |
| 20 | 2018 | 1 |
About Stuart Ince
Stuart Ince is a scholar working on Molecular Biology, Oncology, Cancer Research, Pulmonary and Respiratory Medicine and Hematology, having authored 21 papers that have together received 307 indexed citations. Recurring topics across this work include Fibroblast Growth Factor Research (7 papers), Cancer, Hypoxia, and Metabolism (6 papers), Cancer Treatment and Pharmacology (5 papers), Cancer-related Molecular Pathways (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Advanced Breast Cancer Therapies (4 papers), Protein Degradation and Inhibitors (3 papers) and Epigenetics and DNA Methylation (2 papers). The work is most often cited by research in Oncology (92 citations), Molecular Biology (210 citations), Pulmonary and Respiratory Medicine (62 citations), Cancer Research (26 citations) and Organic Chemistry (54 citations). Stuart Ince has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Dominik Mumberg, Karl Ziegelbauer, Franz von Nussbaum, Arne Scholz, Peter Ellinghaus, Oliver Politz, Mélanie Héroult, Ulf Bömer, Philip Lienau and Ulf Boemer. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, International Journal of Cancer, Molecular Cancer Therapeutics and Journal of Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.